Edesa Biotech (EDSA)
(Delayed Data from NSDQ)
$4.34 USD
-0.02 (-0.46%)
Updated Sep 25, 2024 03:32 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Edesa Biotech, Inc. [EDSA]
Reports for Purchase
Showing records 1 - 20 ( 20 total )
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Government Funds Helping to Advance EB05 in ARDS; Reiterate Buy and $21 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BARDA to Fund Paridiprubart Clinical Study in ARDS; Reiterate Buy and $21 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal 1Q24 Results; EB05 Funding Secured; EB01 Results Look Solid; Reiterate Buy and $21 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Post-Split Model and Pipeline Forecast Changes; Reiterate Buy With an Adjusted PT of $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Final Phase 2b Data Provides Insight Into EB01 Efficacy; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Conditions for a Rapid EB05 Pivotal Study Challenging; Reiterate Buy With PT Adjusted to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Regulatory and Pipeline Progress; Reiterate Buy and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
FDA Agrees to EB05 Phase 3 Primary Endpoint; Reiterate Buy and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
EB05 Phase 3 Trial Approval Pending and Full EB01 Phase 2b Data Analysis Ahead; Reiterate Buy and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Favorable Top-line EB01 Results in Chronic Allergic Contact Dermatitis; Reiterate Buy and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
EB01 Phase 2b Top-Line Data on Track for 1Q23; Reiterate Buy and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
EB05 Receives Fast Track Designation; Reiterate Buy Rating and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Potential EB05 Utility in Difficult-to-Treat COVID-19 Remains Underappreciated; Reiterate Buy Rating and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Expecting EB01 Phase 2b Study Primary Endpoint Within 30 Days; Reiterate Buy and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
EB05 and EB01 Continue to Make Progress; Reiterate Buy and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Momentum Building in EB05 and EB01 Clinical Progress; Reiterate Buy and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
EB05 and EB01 Momentum Going Into 2022 Looking Strong; Reiterate Buy Rating and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Edesa Gets Inflammation Under Control; Initiating Coverage With a Buy Rating and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Edesa Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
|